

OPEN ACCESS

APPROVED BY
Frontiers Editorial C

Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE

Aiiun Sun

Sunaijun0916@163.com

Shasha Zhang

Chao Jiang

ijiangchao1212@126.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 04 July 2025 ACCEPTED 07 July 2025 PUBLISHED 25 July 2025

CITATION

Tian W, Yu C, Xu X, Li J, Peng S, Sun A, Zhang S and Jiang C (2025) Correction: *Myeloid Zinc Finger* 1: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers.

Front. Immunol. 16:1659836. doi: 10.3389/fimmu.2025.1659836

COPYRIGHT

these terms.

© 2025 Tian, Yu, Xu, Li, Peng, Sun, Zhang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with

Correction: Myeloid Zinc Finger 1: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers

Wenze Tian^{1†}, Chun Yu^{2†}, Xin Xu^{3†}, Jiaqi Li⁴, Shuangfu Peng³, Aijun Sun^{3*}, Shasha Zhang^{5*} and Chao Jiang^{6*}

¹Department of Thoracic Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China, ²General Surgery Department, Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai'an, Jiangsu, China, ³Department of Thyroid and Breast Oncological Surgery, Huai'an Second People's Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, Huai'an, Jiangsu, China, ⁴Faculty of Life Science and Food Engineering, Huaiyin Institute of Technology, Huai'an, Jiangsu, China, ⁵Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ⁵Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China

KEYWORDS

Myeloid Zinc Finger 1, pan-cancer, tumor immunity, prognostic biomarker, immunotherapy drug susceptibility

A Correction on

Myeloid Zinc Finger 1: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers

By Tian W, Yu C, Xu X, Li J, Peng S, Sun A, Zhang S and Jiang C (2025). *Front. Immunol.* 16:1591912. doi: 10.3389/fimmu.2025.1591912

Author affiliation

In the article, there was an error in the affiliations. "Affiliation 3, Department of Thyroid and Breast Oncological Surgery, Huai'an Second People's Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, Huai'an, Jiangsu, China", was erroneously omitted for author "Aijun Sun". This affiliation has now been added.

Additionally, author "Aijun Sun" was erroneously assigned to affiliation "2, General Surgery Department, Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai'an, Jiangsu, China". This affiliation has now been removed.

The original version of this article has been updated.

Tian et al. 10.3389/fimmu.2025.1659836

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.